CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled
Drug / intervention
travoprost 0.004% and brinzolamide 1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00471380
NCT00471380Phase 4Completed
CompareCT.gov

A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension

Alcon Research·interventional·Posted May 9, 2007·Updated Mar 16, 2010

In Brief

A Phase 4 clinical trial evaluating travoprost 0.004% and brinzolamide 1% and fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle for Glaucoma and Ocular Hypertension. Completed, enrolled 46 participants across 1 site.

Detailed Summary

Double blind, crossover randomized, multicentric study to compare efficacy and tolerability of concomitant administration of travoprost and brinzolamide versus timolol-dorzolamide fixed combination in patients with glaucoma or ocular hypertension

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesItaly
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 9, 2007
Enrollment StartMar 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.1 years ago

Interventions

travoprost 0.004% and brinzolamide 1%drug

Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)

fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicledrug

group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).